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Cancer remains an undetermined question for modern medicine. Every year millions of 
people ranging from children to adult die since the modern treatment is unable to meet 
the challenge. Research must continue in the area of new biomarkers for tumors. 
Molecular biology has evolved during last years; however, this knowledge has not been 
applied into the medicine. Biological findings should be used to improve diagnostics 
and treatment modalities. 
In this thesis, human formalin-fixed paraffin embedded colorectal and breast cancer 
samples were used to optimize the double immunofluorescence staining protocol. Also, 
immunohistochemistry was performed in order to visualize expression patterns of each 
biomarker. Concerning double immunofluorescence, feasibility of primary antibodies 
raised in different and same host species was also tested.  
Finally, established methods for simultaneous multicolor immunofluorescence imaging 
of formalin-fixed paraffin embedded specimens were applied for the detection of pairs 
of potential biomarkers of colorectal cancer (EGFR, pmTOR, pAKT, Vimentin, 
Cytokeratin Pan, Ezrin, E-cadherin) and breast cancer (Securin, PTTG1IP, Cleaved 
caspase 3, ki67). 
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Ab  antibody 
Anti-EGFR mAb  epidermal growth factor receptor monoclonal antibody 
BC breast cancer 
BRAF human gene that makes a protein called B-Raf 
CC cell culture 
CRC colorectal cancer 
EGFR epidermal growth factor receptor 
FFPE formalin-fixed paraffin embedded 
HRP horseradish peroxidase 
IF immunofluorescence 
IHC immunohistochemistry 
KRAS Kirsten rat sarcoma viral oncogene homolog 
LN lymph node 
MAPK mitogen-activated protein kinase 
2-ME 2-mercaptoethanol 
Ms mouse 
pAKT phosphorylated protein kinase B 
PI3K phosphatidylinositide 3-kinase 
PIK3CA phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
alpha 
p-mTOR phosphorylated mammalian target of rapamycin 
PTEN protein tyrosine phosphatase enzyme 
Rb rabbit 
SDS sodium dodecyl sulfate 
TMA tissue microarrays 
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1. REVIEW OF THE LITERATURE 
Cancer, malignant disease originating from epithelial cells, is characterized by 
aggressive cell growth, invasion and metastasis - an ability to spread to other parts of 
the body (www.cancer.gov, 2015).  Cancer is the major cause of morbidity and 
mortality in the population: 14 million new diagnoses and 8.2 million cancer deaths 
were reported worldwide in 2012 (Bernard et al., 2013). 
 
1.1 Colorectal cancer  
 
Colorectal cancer (CRC) is the third most common cancer worldwide (World Cancer 
Research Fund 2007). Around the world, approximately 1 million of people are 
diagnosed with colorectal cancer every year, one fourth of them have metastatic 
disease at the time of diagnosis and another one fourth will develop metastases during 
the course of their disease (Parkin et al., 2002). Life expectancy of metastasized 
colorectal carcinoma remains short in spite of new treatment modalities (Wang et al., 
2011). Therefore, research on tumor markers to improve the diagnostics, detection of 
residual disease, and prognostic and predictive features is extensive (Beachy and 
Repasky, 2008).  
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine kinase 
commonly overexpressed or mutated in many human cancers, including e.g. 
carcinomas of the breast, lung, head and neck, bladder, kidney, ovary and colorectum. 
EGFR and its downstream components mediate growth promoting signaling and thus, 
serve as a target for molecular therapy (Figure 1). (Krasinskas, 2011). EGFR signaling 
pathway is activated when a ligand binds EGFR and induces dimerization of the 
receptor, resulting in the activation of tyrosine kinase. The intracellular tyrosine kinase 
residues participate in an autophosphorylation process that leads to the activation of 
multiple signal transduction pathways. The two main signaling pathways controlled by 
EGFR are the mitogen-activated protein kinase (MAPK) pathway and the 
phosphatidylinositol 3-kinase- (PI3K-) protein kinase B (AKT) pathway. These two 
signaling pathways lead to activation of several transcription factors that regulate 
proliferation, differentiation, migration, and apoptosis. (Citri and Yarden, 2006.) Failure 
in the signaling system promotes cell growth, malignancy, metastatic dissemination 
and resistance to apoptosis (Krasinskas, 2011).  
Treatment of colorectal cancer consists of several possible modalities and, depending 




excision of the tumor can be associated with chemotherapy, radiotherapy, targeted 
therapy or a combination of different treatments. Targeted therapies include drugs 
inhibiting VEGF of EGFR signaling. (www.cancer.org, 2015.) Several downstream 
effectors of EGFR have been shown to have a predictive value for anti-EGFR 
treatment (Neumann et al, 2013). For example, KRAS, a downstream molecule in 
EGFR signaling cascade, has been detected with a mutation in 40 % of CRC cases 
(Bouche et al., 2010). Patients with activating KRAS mutation are resistant to 
epidermal growth factor receptor monoclonal antibody (anti-EGFR mAb) treatment 
(Lievre et al., 2006). Additionally, only every third of patients exhibiting wild-type KRAS 
will benefit from anti-EGFR mAb treatment (Chang et al., 2009). In literature, metastatic 
cancers with wild-type KRAS and BRAF mutations have been associated with shorter 
overall survival (Laurent-Puig et al., 2009). Among metastatic colorectal carcinomas 
that represent/exhibit the KRAS wild type, 5% to 15% can harbor BRAF mutations and, 
thus, have resistance to anti-EGFR therapy (Loupakis et al., 2009). Additionally, the 
PI3K-AKT signaling pathway may not function correctly because of mutations in 
PIK3CA gene, inactivation of protein tyrosine phosphatase enzyme (PTEN) gene or 
activation of p-AKT (Hynes and Lane, 2005). For example, patients with a mutation in 
exon 20 of PIK3CA gene do not benefit from targeted treatment using monoclonal 
antibodies (De Roock et al., 2010). PTEN is a protein that inhibits the function of PI3K 
(Hynes and Lane, 2005). Therefore, loss of PTEN leads to activation of the PI3K-AKT 
pathway (Laurent-Puig et al., 2009). p-AKT expression is associated with low stage of 
the cancer and favourable prognosis (Baba et al., 2011).  
Obviously, accurate information on the mutations and their concordance with the 
expression of EGFR signaling molecules in CRC are needed for improved diagnostics 





Figure 1. EGFR signaling pathway. Modified from Krasinskas, 2011. EGFR signaling pathway is 
activated when a ligand binds EGFR and induces dimerization of the receptor, resulting in the 
activation of tyrosine kinase. The intracellular tyrosine kinase residues participate in an 
autophosphorylation process that leads to the activation of multiple signal transduction 
pathways. The two main signaling pathways controlled by EGFR are the mitogen-activated 
protein kinase (MAPK) pathway and the phosphatidylinositol 3-kinase- (PI3K-) protein kinase B 
(AKT) pathway. These two signaling pathways lead to activation of several transcription factors 
that regulate proliferation, differentiation, migration, and apoptosis. (Citri and Yarden, 2006.) 
 
1.2 Breast cancer  
Breast cancer (BC) is the most common cancer in women worldwide, and about 1.7 
million new cases were diagnosed in 2012 (Ferlay et al., 2012).  
Breast cancer is clinically a heterogeneous disease where the outcome of the patient is 
dependent on several features, particularly the histological type and grade, tumor size, 
nodal involvement and Estrogen Receptor (ER) and Human Gene of Epidermal Growth 
Factor Receptor 2 (HER2) status. Many new classification methods have been 
proposed but up till now in clinical routine the diagnostic and therapeutic decision-
making is still based on the traditional histological type and grade with expression 
status of hormone receptors and HER2 (Lakhani et al., 2012). More recently, gene 
expression profiling has provided a molecular basis for breast cancer classification 
(Perou et al., 2000). Currently surrogate immunohistochemical criteria are applied to 




corresponding to the molecular classification (Goldhirsch et al., 2011). In routine clinical 
diagnostics, breast cancer can be classified into Luminal A, Luminal B, HER2-enriched, 
Claudin-low, Basal-like and Normal Breast-like groups (Figure 2) (Prat and Perou, 
2011). The use of the intrinsic classification is grounded by the observed significant 
survival difference between the patient subgroups (Sorlie et al., 2003). Routine clinical 
diagnostics based on ER, PR and HER2 is insufficient to predict sensitivity to 
treatment. Luminal type of breast cancer is thought to be a derivative from normal 
luminal breast epithelium. Overexpression of ER and low expression of HER2 are 
distinctive for luminal A type and for this reason it is sensitive to hormonal therapy and 
associated with long-term survival. (Hu et al., 2006.) Luminal B type, in turn, is 
characterized by high expression of HER2, low expression of ER, high proliferation and 
less favourable prognosis (Sorlie et al., 2001).  
Traditional breast cancer biomarkers are ER, Progesterone Receptor (PR) and HER2. 
Hormone receptor-positive carcinomas are best treated with hormonal therapy whereas 
patients lacking ER and PR-receptors are commonly considered not to benefit from 
hormonal treatment. According to literature, recurrences in ER-positive carcinomas 
occur only after 10-20 years and, consequently, ER is an established biomarker for 
favourable prognosis in breast cancer (Harris et al., 2007.) Approximately 12-15% of 
breast carcinomas exhibit HER2-amplification. The HER2 protein facilitates cancer cell 
growth and, as a result, aggressive behavior and progression of breast carcinoma. 
Patients with HER2-amplified breast carcinomas are offered a special Her2-targeted 
treatment, most commonly trastuzumab. According to literature, ER- and PR-positive 
breast carcinomas are less aggressive than HER2-positive carcinomas. The most 
aggressive breast cancer subtype is the so called triple-negative cancer which is 
ER/PR-negative and lacks HER2-amplification. This carcinoma subtype shows 
particularly rapid growth and high risk of recurrence (Foulkes et al., 2010). Triple-
negative breast carcinomas are more common in young women (<40 years) and often 
associated with BRCA1 mutations (Young, 2009). BRCA1 and 2 are tumor suppressor 
genes, which are normally expressed in breast and several other tissues. In case of 
BRCA1/2 mutation, the normal DNA repair mechanism called homologous 
recombination is hampered predisposing the cell to increased mutational load and 
malignant progression (Friedenson, 2007). Ki67 is a marker of cell proliferation. Ki67 
immunohistochemistry has relative prognostic value, especially in luminal B subtype of 
breast carcinomas. According to several reports, the prognostic value of Ki-67 is, 






Figure 2. Molecular classification of breast cancer. Modified from Malhotra et al.,2010. 
According to most recent gene expression studies, breast cancer classification includes 
Luminal A, Luminal B, HER2-enriched, Claudin-low, Basal-like and Normal Breast-like 
groups (Figure 2). (Prat and Perou, 2011.). A subtype of triple-negative breast 
carcinomas, namely basal carcinoma has attracted attention in the recent years due to 
its aggressive course of disease. Gene expression pattern of basal like resembles that 
of basal cells of the normal breast epithelium and expresses cytokeratins 5/6 and 17, 
integrin 4 and laminin. Basal subtype of breast carcinoma is regularly triple-negative, 
with frequent mutations in the BRCA1, BRCA2, ATM and TP53 genes, RB1 loss and 
cyclin E1 amplification (Cancer Genome Atlas Network, 2012.). Low expression of 
genes involved in tight junctions and cell-cell adhesion, such as claudins and E-
cadherin are represented in the recently discovered Claudin-low subgroup of breast 
carcinomas which is also associated with markers of epithelial-to-mesenchymal 
transition (EMT) (Herschkowitz et al., 2007.) Both of these breast carcinoma subtypes 
are associated with unfavourable outcome of disease (Prat et al., 2010). In addition to 
the above mentioned progress, research in proteomics and gene-expression analysis 
is constantly facilitating discovery of new biomarkers in breast cancer. Numerous 
biomarkers are presently under investigation, for example related to the p53, RB, 
PI3K/Akt/mTOR and Ras/MAPK pathways, as well as alterations associated with 
genetic instability and epigenetics including histone methylation and acetylation, DNA 
methylation and microRNAs expression (Kourea et al., 2015). Clearly, further research 
and new biomarkers are needed for more accurate diagnostics and treatment, as well 





1.3 Principle of immunohistochemical staining method  
Much biological, chemical and molecular information about disease can be obtained 
from formalin-fixed paraffin embedded (FFPE) tissue samples. Along with conventional 
morphology, immunohistochemistry (IHC) is a microscope-based technique of wide 
clinical use. The technique aims to identify specific cellular biomarker molecules, which 
are not visible using common hematoxylin and eosin staining. (Brandtzaeg, 1998.) In 
the area of cancer diagnostics, IHC is used to detect tumor markers to assess, whether 
the tumor is benign or malignant, to evaluate the origin of the tumor, to establish 
prognosis, or to predict the effect of cancer treatment. (Harsh, 2005.)  
Preparation of FFPE specimen consists of tissue fixation, processing and sectioning. In 
general outline, immunohistochemical staining consists of slide preparation, specific 
reactions applying primary antibodies and detection of bound antibodies. More 
precisely, basic procedure usually includes antigen retrieval, different blocking steps, 
primary antibody incubation in specific solution at appropriate concentration, detection 
of primary antibody, counterstaining and mounting. (Brandtzaeg, 1998.) In IHC, primary 
antibody denotes the antibody which specifically recognizes the target protein of 
interest. The secondary antibody, on the other hand, recognizes the primary antibody. 
Secondary antibodies are labelled with e.g. enzymes. There are different types of 
chromogens serving as substrates for these enzymes enabling the visualization of the 
antigen-antibody complex by light microscopy. (Taylor et al., 2013.) 
There are several choices for the detection of primary antibodies. The ability of avidin 
to bind with high affinity and specificity to biotin is utilized in avidin-biotin complex 
method. Biotin can bind four avidin molecules. Therefore, the usage of secondary 
antibody conjugated with biotin, following by the application enzyme-avidin complex 
amplifies the signal derived from primary antibody. Alkaline phosphatase or 
horseradish peroxidase (HRP) is typically used as an enzymatic label in this method. 
Streptavidin-biotin method is based on avidin-biotin method. However, complex is 
smaller in size and, hence, reaches more easily difficult to access targets. Using 
phosphatase-anti-phosphatase (PAP) method even higher sensitivity is achieved. In 
this method, unconjugated secondary antibodies are applied, resulting in attachment of 
two secondary antibodies to one primary antibody (Figure 3). A tertiary antibodies 
conjugated with peroxidase is then used to detect secondary antibodies. Multiple 





Figure 3. Principle of signal amplification utilizing phosphatase-anti-phosphatase (PAP) method. 
Target antigen (yellow) is recognized by primary antibody (red), which is recognized by two 
secondary antibodies (blue). A tertiary antibodies conjugated with peroxidase (green) is then 
used to detect secondary antibodies, amplifying the signal greatly. Modified from Snider, 2014. 
To avoid a well-known limitation of avidin-biotin system, i.e. background staining due to 
endogenous biotin in tissue, and to further increase signal intensity, modern polymer-
based detection techniques have been introduced. These methods apply a polymer 
backbone conjugated with several secondary antibodies and reporter enzymes (Chilosi 
et al., 1994). If even higher intensity is required, tyramide signal amplification system 
(TSA) can be used. It has been reported to increase the signal 50 times higher 
compared to that detected without amplification. In this technique peroxidase is utilized 
to activate tyramide which is then covalently bound to proteins in tissue immediately 
adjacent to the sites where peroxidase is immobilized (Figure 4). Multiple depositions 
of activated tyramides occur in short period of time amplifying the original signal 
greatly. Tyramide derivatives are most often fluorescently labeled. However, hapten 
labelled tyramides and choromogenic substrates have also been introduced. 
(www.perkinelmer.com.)  
Figure 4. Schematic representation of TSA detection method. The antigen is detected by a 
primary antibody, followed by a horseradish peroxidase HRP-labeled secondary antibody in 
connection with a dye-labeled tyramide, resulting in localized deposition of the activated 
tyramide derivative (Stage 1). Further dye deposition, and consequently higher levels of signal 
amplification, can be constituted by detecting dye deposited in Stage 1 with a HRP-labeled anti-





In IHC, strong staining of background is occasionally seen unrelated to target signal 
and interfering with the interpretation of the result. For example, staining methods 
based on biotin, or peroxidase and phosphatase reporters are prone to show high 
background staining if endogenous forms of these molecules have not been quenched. 
Other possibilities causing background staining are cross-reactivity and nonspecific 
binding of an antibody. Nonspecific binding of primary antibody to nontarget epitopes is 
often caused by high concentration of primary antibody. (Snider, 2014.) Additional 
blocking step using, for example, bovine serum albumin (BSA) or milk may be needed 
to avoid this problem (Duhamel and Johnson, 1985.) 
Another problem associated sometimes with IHC is a weak target signal, meaning too 
weak intensity of the signal due to suboptimal conditions used in staining. Weak 
staining of a target has been associated with enzyme-substrate reactivity, primary 
antibody potency and secondary antibody inhibition. For proper enzyme-substrate 
reactivity, pH of the substrate buffer should be optimized. (Taylor et al., 2013.) The 
potency of antibody denotes specific ability of primary antibody to yield sufficiently high 
signal intensity in the detection of target of protein. Interestingly, extremely high 
concentrations of secondary antibody have been shown to inhibit the intensity of the 
signal achieved. Also, care must be taken when handling primary antibody to avoid its 
inactivation by multiple freeze-thaw cycles or long-term storage. (Snider, 2014.) 
1.4 Fluorescence microscopy  
Fluorescence microscopy utilizes fluorescence or phosphorescence and the principles 
of absorption and reflection in substances. The technique is important in both biological 
and medical sciences.  
The structure of wide-field fluorescence microscope enables to efficiently collect 
fluorescent light which forms the image. The composition of the microscope makes it 
possible to first illuminate the sample with excitation light and then to remove the 
scattered signal from emitted light. A set of filters, definite for a particular wavelength, is 
used to obtain the final image (Demchenko, 2008). In multicolor fluorescence 
microscopy various fluorophores are applied onto one specimen. Multicolor images are 






1.5 Principle of immunofluorescence staining method  
Immunofluorescence (IF) microscopy is a technique very similar to 
immunohistochemistry. The only difference is the utilization of fluorescent reporter 
molecules instead of chromogenic ones in the detection. There are several different 
possibilities of the application of fluorescent detection; for example, fluorescently 
labelled primary antibody, fluorescently labelled secondary antibody, and biotin-labelled 
secondary antibody detected with fluorescently labelled streptavidin. Furthermore, 
fluorescently labelled tyramides can be applied if the TSA system is used. (Odell and 
Cook, 2013; abcam.com.) 
Fluorophores are compounds, characterized by an ability to emit light upon light 
excitation. They absorb light of a specific wavelength and emit it at a different 
wavelength.  Fluorescein isothiocyanate (FITC), derivative of fluorescein, is one of the 
most widely used fluorophores. Other common fluorophores are derivatives of 
rhodamine (especially tetramethylrhodamine, i.e. TRITC), coumarin, and cyanine. 
(Rietdorf J, 2005.) Newer fluorophores, such as pyrene, coronene and lanthanides 
have been developed for brighter signal, diminished pH-sensitivity and/or to overcome 
the inherent problem of photo-lability of fluorophores (Tsien and Waggoner, 1995; 
Lakowicz, 2006), meaning the loss of signal over time with exposure to light - also 
called bleaching (Odell and Cook, 2013). 
The problems of background staining and weak target signal are common for IHC and 
IF. As with IHC, the quality of the signal in IF depends on many technical details of the 
staining protocol, such as quality and concentrations of antibodies applied (Odell and 
Cook, 2013). In IF, a specific problem associated with FFPE samples is 
autofluorescence. It means natural emission of light by biological structures often 
difficult to distinguish from that of added fluorescent reporters. Tissue sample may 
show inherent autofluorescence or fixation method, such as aldehyde, may cause it. 
For example, blood vessels may show inherent autofluorescence. FFPE samples may 
have autofluorescence also from paraffin even after clearing. (Snider, 2014; Davis et 
al., 2014.) TSA method can be applied to increase particularly the signal obtained from 
target, thereby helping to resolve the problem of autofluorescence. However, 
undesirable fluorescence can be caused by nonspecific binding of dye or unbound dye. 
(www.thermofisher.com.) 
Photobleaching also is considered as one of disadvantage of fluorescent stainings 




It is particularly beneficial when identifying simultaneously several antigens in one 
specimen utilizing fluorescent labeling with several dyes. For example, Mason et al 
(2000) have published a method for double IF in routinely processed paraffin section 
and Brouns et al (2002) have described a method for triple IF staining. 
 
1.6 Simultaneous detection of multiple antigens using 
immunohistochemistry and immunofluorescence  
Either chromogenic or fluorescent reporters can be used in the detection of multiple 
antigens (Taylor et al., 2013). Robertson and coworkers (2008) have presented 
simultaneous detection of even three antigens in one tissue section. In double labeling 
a combination of two primary antibodies is used to detect two targets. Some specific 
problems should be taken into account and resolved in the optimization of the protocol 
for double staining.  
First, most of the primary antibodies available are raised in mouse or rabbit, but it is 
often hard to find a pair of primary antibodies raised in different host species for the 
detection of particular targets of interest. This leads to a problem of cross reaction if 
indirect detection method using species specific secondary antibodies are applied 
instead of utilization of directly labelled primary antibodies. However, directly labelled 
primary antibodies are expensive and the sensitivity of the detection is low (Boorsma, 
1984; Stengl and Hildebrand, 1990).  Alternatively, pair of primary antibodies from 
same host species but of different isotype or subclass may be used. In practice, this 
applies mainly for mouse monoclonal primary antibodies since rabbit monoclonal 
antibodies are usually of IgG isotype and rabbit has only one IgG subclass, while e.g. 
mouse has five different IgG subclasses. (Taylor et al., 2013.) Besides to difficulties 
related to the availability of primary antibodies, also selection of fluorescent reporter 
molecules with minimally overlapping spectral characteristics, and at the same time 
stable and bright signal may sometimes be an issue for double immunofluorescence 
(Van Der Loos, 2014.). Nevertheless, many different fluorescent compounds have 
been launched in recent years to solve the problem (Zheng et al., 2014).  
There are some specific limitations associated with double IHC in comparison to 
double IF. As to spectral differentiation, it is even more challenging when chromogenic 
reporters are in question. Especially, when the targets of interest are colocalized into 
the same cellular compartment, mixed colors of chromogens are hard to differentiate. 




unmixing (van der Loos, 2008).  In that case, fluorescent reporters are more convenient 
to use. However, an advantageous characteristic of precipitate formation is associated 
with DAB and utilized in double IHC when primary antibodies raised in one host 
species need to be applied. This means that precipitate formed by DAB-substrate 
shelters (Figure 5) the first primary antibody after the detection of the first target and 
prior to the detection of the second target. Thereby, the precipitate blocks the cross 
reaction between the first primary antibody applied and the secondary antibody used 
for the detection of the second target. (Sternberg and Joseph, 1979.) However, 
concentration of primary antibody may affect the result, and if used at too high 
concentrations, leaves the complex unsheltered (Van der Loos 2008). Additionally, 
sheltering is not recommended for colocalization studies (Van der Loos 2008), because 
one of the closely located targets may be missed by sheltering (Valnes and Brantzaeg, 
1984.) 
 
Figure 5. Principle of sheltering effect by DAB-precipitate in sequential double IHC applying two 
primary antibodies raised in mouse and anti-mouse secondary antibodies. Modified from Van 
der Loos, 2008. Precipitate formed by DAB-substrate shelters the first primary antibody after the 
detection of the first target and prior to the detection of the second target. Thereby, the 
precipitate blocks the cross reaction between the first primary antibody applied and the 
secondary antibody used for the detection of the second target. (Sternberg and Joseph, 1979.) 
 
1.6.1 Double IF using primary antibodies raised in different host 
species 
Primary antibodies raised in two different host species are commonly used in double 
immunofluorescence staining. Bound primary antibodies can be detected, for example, 
by indirect method using species-specific secondary antibodies conjugated with 
fluorophores. Typical protocol for FFPE tissue includes following steps (Buchwalow 






1. Deparaffinization and rehydration.  
2. Antigen retrieval, for example by protease digestion or in buffer (e.g. citrate 
buffer, pH 6) in microwave oven, autoclave or pressure cooker. 
3. Blocking of unspecific reactions of antibodies by incubation in solution 
containing e.g. BSA, gelatin or nonfat dry milk, or in serum of animal species, in 
which secondary antibody was raised.  
4. Primary antibodies applied simultaneously as cocktail (raised in e.g. mouse and 
rabbit).  
5. Secondary antibodies labelled with different fluorophores applied 
simultaneously as cocktail (e.g. anti-mouse and anti-rabbit).  
6. Counterstaining of DNA material in nuclei with DAPI.  
7. Mounting.  
If high signal intensity is needed, also TSA can be applied, and multicolor labelling is 
typically applied sequentially utilizing horseradish peroxidase labelled secondary 
antibodies. In that case, enzyme activity used in the detection of the first target must be 
totally quenched before the detection of the next one. Otherwise, false signal - derived 
from enzymatic activity of the first secondary antibody and of the second fluorescent 
tyramide substrate - can be observed. There are several possibilities for quenching the 
enzymatic activity of HRP described in literature, such as treatment in hydrogen 
peroxide or hydrochloric acid, or boiling. (www.perkinelmer.com, 2015; Roth K, 2008.) 
 
1.6.2 Double IF using primary antibodies raised in same host 
species 
As described above, it is often difficult to find pairs of primary antibodies suitable for 
diagnostic use and/or raised in different host species. In literature, different variations 
of immunofluorescence methods have been introduced to overcome this problem. For 
example, primary antibodies can be directly labelled with fluorophores (Tsirui et al., 
2000) but this type of staining is not as sensitive as an indirect one and large amount of 
antibodies is needed. Therefore, indirect methods are in wider use. (Van der Loos 
2008). One possibility is to use primary antibodies from one host species but different 
immunoglobulin isotypes. In this case, isotype specific secondary antibodies are 
utilized (Buchwalow et al., 2005). In sequential double IF the detection of the first target 
can be performed using a system with greater sensitivity compared to that of the latter 
target. In that case, the first primary antibody is applied at very low concentration, and 




does not cause a visible problem. Furthermore, some authors describe monovalent 
Fab fragments to block residual binding sites on the first primary antibody prior to the 
application of the latter secondary antibody (Brouns et al., 2002; Lewis Carl et al., 
1993). 
To overcome limitations related to the availability of primary antibodies, publications 
report also on elution or denaturation of an antibody after the detection of the first 
target. In these staining methods, covalent binding of fluorescent tyramides to tissue 
can be employed, thus enabling usage of harsh treatments in removal of the antibodies 
already used. If the elution or the denaturation succeeds primary antibodies raised in 
one host species and of the same isotype can be used to detect the second target. 
Obviously, success of removal has to be monitored with proper controls. (Bauer et al., 
2001.)  
Toth and Mezey (2007) have described a heat-mediated stripping method of boiling in 
citrate buffer for the elution of rabbit primary antibody after first round of IF. Likewise, 
Ikeda et al (2011) have used heating in citrate buffer and found that time needed to 
elute different primary antibodies differs a lot and thus, time of treatment should be 
optimized for each antibody individually. They have reported that several antibodies 
can survive detectable even after 60 min treatment. That’s why, the order of the 
application of primary antibodies can often be crucial, too. (Ikeda et al., 2011). Also, the 
usage of different types of treatments of the specimen in a microwave oven may be 
tested as long as the target to be detected after the treatment is stable under these 
conditions (Toth and Mezey, 2007; Lan et al 1995). Nevertheless, sometimes treatment 
in a microwave oven can’t completely exclude the signal obtained from the first 
detected target. For example, study published by Bauer et al (2001) shows that 
desmin, ASM-1 and ki-67 antigens can’t be denaturated by microwave treatment. 
Various chemical treatments have also been tested for the elution of the antibodies, 
such as acidic solutions, like buffered glycine-hydrochloric acid and unbuffered 
hydrochloric acid, or buffered solution containing SDS and di-thiothreitol (Nakane, 
1968). Also, a buffer containing glycine and SDS, and having low pH-value, has been 
proposed. (Pirici et al., 2009.) Recently, Gendusa et al (2014) published an extensive 
study showing that some antibodies are able to survive detectable even after 
application of harsh conditions such as pH 2, temperatures above 600 and chaotropic 
agents. They found that 2-Mercaptoethanol/Sodium dodecyl sulfate (2-ME/SDS) is the 
most efficient solution of the tested ones for the elution of antibodies leaving most 
antigens embedded in tissue untouched though. However, it was also shown that 




For some antibodies, having low affininity, usage of either acidic solution or hot 
chaotropic agent was enough for efficient elution, while 2-ME/SDS-treatment was 
required for high affinity antibodies. Furthermore, the authors state that monoclonal 
antibodies with high affinity may require multiple elution steps. (Gendusa et al., 2014.) 
Rabbit monoclonal antibodies are characterized by a higher affinity to their target 
epitopes compared to mouse monoclonal and rabbit polyclonal antibodies (Pope et al., 
2009).  
2. AIMS  
 
This thesis concentrates on establishing a technique for the visualization of multiple 
antigens in human formalin-fixed paraffin embedded tissue by immunofluorescence. 
The specific aim is to test the applicability of tyramide signal amplification system to 
overcome the inherent problem of autofluorescence seen in FFPE specimens. 
Additional emphasis is to explore the utilization of two primary antibodies raised in one 
host species in multicolor imaging. Medical focus is given on selected biomarkers for 
colorectal and breast cancer with special attention to the EGFR-signaling for CRC and 
proliferation related protein securin for BC. 
3. MATERIALS AND METHODS 
 
3.1 Tissue material and reagents 
Archival tissue samples from patients treated for colorectal or breast cancer were 
obtained from the Department of Pathology, Turku University Hospital. Additionally, 
lymph node tissue was used for control and optimization purposes. Specimens had 
been fixed in neutral buffered formalin and embedded in paraffin according to routine 
processing of tissue samples in the Department of Pathology. They were cut in 3-4 µm 
sections and placed onto SuperFrost Plus (Thermo Scientific, cat. J1800AMNZ) 
microscope slides. Sections were kept in an incubator overnight at 60 °C to melt 
paraffin and to attach tissue on slide. 
Primary antibodies used in the study are described in table 1. Diluents used for the 
preparation of primary antibody dilutions were Antibody Diluent (Roche/Ventana, cat. 
251-018), Discovery PSS Diluent (Roche/Ventana, cat. 760-212), DAKO REAL 
Antibody Diluent (Dako, cat. S2022) and Signal Stain (R) Antibody diluent (Cell 




Table 1. List of the primary antibodies used in the study  
Antibody Type Clone Manufacturer 
EGFR mouse monoclonal 25 Abcam cat. ab 49716 
EGFR rabbit monoclonal 5B7 Ventana cat. 790-4347 
p-mTOR 2448 rabbit monoclonal 49F9 Cell Signaling Technology 
cat. 2976 
pAKT 473 rabbit monoclonal EP209Y Abcam cat. 81283 
pAKT 473 rabbit monoclonal D9E Cell Signaling Technology 
cat. 4060 
Vimentin  mouse monoclonal V9 Ventana cat. 790-2917 
E-cadherin  mouse monoclonal NCH-38 DAKO cat. M3612 
Cytokeratin Pan  mouse monoclonal AE1/AE3 Invitrogen cat. 180132 
Ezrin mouse monoclonal 3C12 Olli Carpén Lab, Helsinki 
Cleaved caspase 3 
Asp175 
rabbit monoclonal D3E9 Cell Signaling Technology 
cat. 9579S 
Securin mouse monoclonal DSC-280 Abcam cat. ab 3305 
Securin rabbit monoclonal EPR 3240 Abcam cat. ab 79546 
PTTG1IP rabbit polyclonal - Abcam cat. ab 128040 
ki67  rabbit polyclonal - Millipore AB9260 
 
In IHC, commercial pre-formulated buffers CC1 and CC2 (Roche/Ventana, cat. 950-
124 and 950-123, respectively) were used in antigen retrieval, and OmniMap anti-ms 
HRP (Roche/Ventana, cat. 760-4310) and OmniMap anti-rb HRP (Roche/Ventana, cat. 
760-4311) multimer secondary reagents together with ChromoMap DAB substrate kit 
(Roche/Ventana, cat. 760-159) were used for the detection of primary antibodies. 
Counterstaining was performed using Hematoxylin II (Roche/Ventana, cat. 790-2208) 
and Bluing Reagent (Roche/Ventana, cat. 760-2037). Deparaffinization solution 
EZPrep (Roche/Ventana, cat. 950-102) and Reaction Buffer (Roche/Ventana, cat. 950-
300) used in IHC-staining were purchased from Roche. Pertex (Histolab, cat. 00811) 
was applied for mounting. 
In IF, antigen retrieval solutions Target Retrieval Solution pH 6.1 and Target Retrieval 
Solution pH 9.0 (Dako, cat. S169984-2 and S236784-2, respectively) were applied. 
TSA-kits 2 and 41 (Molecular Probes by Life Technologies, cat. T30954 and T20912) 
were used in the detection of primary antibodies and ProLong Gold antifade reagent 




stainings included also following reagents: SDS 99% (Sigma, cat. L4390), Trizma base 
(Fluka analytical, cat. 93352), Riboclear (Ventana, cat. 760-4125), xylene (VWR, cat. 
1307), ethanol (VWR, cat. 1170), 30 % hydrogen peroxide (VWR, cat. 2014) and 2-
Mercaptoethanol (Pharmacia Biotech, cat. 17-1317-01). 10x Phosphate-buffered saline 
(PBS) was prepared from NaCl (JT Baker, cat. 0278), KCl (Merck KGaA, cat. 
4089933), Na2HPO4 (JT Baker, cat. 141965) and KH2PO4 (Merck KGaA, cat. 104873) 
(recipies and calculations included in the appendices). 
3.2 Immunohistochemical staining 
Fully automated DISCOVERY XT (Roche/Ventana) platform was utilized in 
visualization of expression patterns of specific biomarkers prior to application of same 
primary antibodies in IF-stainings. DISCOVERY XT slide staining system is computer 
controlled and automates the process from deparaffinization to counterstaining. It 
allows choice from multiple predetermined options of pretreatment conditions as well 
as blockers and detection systems. In this system, all incubations are performed under 
oil coverslip on individually heated hotplates. 
In the optimization of each staining, different antigen retrieval buffers and incubation 
times, as well as varying dilutions, incubation times and temperatures for primary 
antibodies, were applied. Usually, several combinations of conditions had to be tested 
for optimal result. Sometimes, various incubation times for secondary antibody 
multimers needed to be tried, too, to increase signal obtained using certain primary 
antibodies (tables included in the appendices). In this study, diluted primary antibodies 
were added manually onto each slide during staining run applying volume of 100 µl per 
slide for each staining. After counterstaining slides were collected and washed using 
mild dishwashing liquid (Fairy Original, P&G) to remove oil coverslip. Finally, slides 
were manually dehydrated in series of ethanol and xylene and mounted for light 
microscopy.   
3.3 Immunofluorescence staining and fluorescence microscopy 
IF-staining was performed manually utilizing TSA-system. The basic protocol 
recommended by Life Technologies was followed. However, optimal dilutions of 
secondary antibodies and fluorescent tyramide conjugates were tested before 
proceeding to the optimization of double labellings. In double IF, the protocol 
developed for single IF was utilized applying it sequentially two times for detection of 
two antigens. Pairs of primary antibodies raised in either different or same host species 
were tested. More detailed description of different treatments applied between 




stainings were performed leaving out different combinations of detection reagents to 
control for possible autofluorescence, endogenous peroxidase activity and cross 
reactions. The applicability of the developed single and double IF basic protocols were 
further tested using several primary antibodies for different biomarkers. In these 
stainings, dilutions of primary antibodies were optimized for each biomarker using 
single IF before proceeding to double labelling.  
In IF, sections of FFPE tissues were first sequentially treated with xylene and series of 
graduated ethanol to remove paraffin, and rinsed in distilled water. Heat mediated 
antigen retrieval was performed in common household microwave oven in 200 ml of 
buffer with specific pH value. Two different buffers (pH 6.1, 0.1x Dako and pH 9.0, 1x 
Dako) were used in this study. The power settings in microwave treatment were, first, 
600W 7 min, and then 450W 7 min. After the treatment slides were let to cool down 20 
min on the table. Quenching of the endogenous peroxidase activity was performed in 
freshly prepared 3% hydrogen peroxide solution. Subsequently, slides were treated 
with 1% BSA solution to block unspecific interactions between antibodies and tissue 
components. Then, primary and HRP-conjugated secondary antibodies were 
sequentially applied on sections following by the application of Alexa Fluor 488 or 
Alexa Fluor 555 tyramide substrate to visualize target. Finally, sections were 
counterstained and mounted with antifade reagent containing DAPI. Slides were 
incubated at room temperature in dark, then sealed with nail polish and stored in fridge. 
In the protocol described above, slides were rinsed three times with 1x PBS solution 
prior to the quenching of endogenous peroxidase activity and following the incubations 
with primary and secondary antibodies. Rinsing and quenching steps were performed 
in a jar in large volume of solutions. However, other incubations were carried out in 
humidified chamber. In that case, smaller volume of reagents, typically from 100 to 250 
µl, was used depending on the size of the tissue section on the slide. Tyramide stock 
solution, horseradish peroxidase (HRP) conjugate stock solution and amplification 
buffer in H2O2 were prepared according to the instructions of TSA-kit. Tyramide stock 
solution and HRP conjugate stock solution were diluted just before use in each 
staining.  
Slides were examined with wide-field microscope Leica DM RXA (upright). Three filter 
sets were applied for fluorescent signal detection: blue for DAPI (excitation filter BP 
340-380, dichromatic mirror 400, suppression filter LP 425, Leica code A), green for 
Alexa488 (emission wavelengths 450-490nm) and red for Alexa555 (emission 





Summary of single-IF protocol for FFPE tissue specimens: 
1. Overnight incubation at +60 °C 
2. Deparaffinization 
3. Rehydration in series of xylene and descending ethanols, finally to distilled 
water 
4. Antigen retrieval  
5. Endogenous peroxidase quenching, 60 min at RT 
6. Blocking, 60 min at RT 
7. Primary antibody labeling, 60 min at RT  
8. Rinsing 3 times with 1xPBS 
9. Secondary antibody labeling, 60 min at RT 
10. Rinsing 3 times with 1xPBS 
11. Alexa Fluor tyramide labeling, 10 min in dark at RT 
12. Rinsing 3 times with 1xPBS 
13. Mounting  
3.3.1 Double IF using primary antibodies raised in different host 
species 
Double IF using primary antibodies raised in different host species was performed 
sequentially combining two pre-optimized single IF stainings. Schematic diagram below 











Deparaffinization, rehydration, antigen retrieval, endogenous 
peroxidase quenching, and blocking. 
 
Tested options for the inactivation of the HRP-activity: 
1. Treatment with 0.3% H2O2 for 30 min at room temperature 
in a jar (designated as 0.3% H2O2 ) 
2. Treatment with 2% H2O2 for 30 min at room temperature in 
a jar (designated as 2% H2O2 ) 
3. Treatment with 0.01 M HCl for 10 min at room temperature 
in a jar (designated as HCl) 
4. Treatment by boiling in distilled water for 1 min in a jar 
(designated as 1 min boiling).  
 
Detection of the first target: primary antibody labeling, secondary 









3.3.2 Double IF using primary antibodies raised in same host 
species 
Double IF using primary antibodies raised in same host species was performed 
sequentially as described in the schematic diagram included in the previous section. 
However, types of treatments applied between the detections of targets differed from 
those represented previously. In this case, a specific purpose was to elute or to 
denaturate the primary antibody which has already been detected – along with 
inactivation of HRP-activity – in order to avoid cross reaction between the first primary 
and the second secondary antibody. In this study, following combination of treatments 
were applied between the detections of the first and the second target:  
1. Boiling for 1 min in distilled water (designated as 1 min boiling) 
2. Boiling for 3 min in distilled water (designated as 3 min boiling) 
3. Treatment with Riboclear for 10 min at 37 C, and rinsing 3 times with 1xPBS 
(designated as Riboclear) 
4. Treatment with Riboclear for 10 min at 37 C, and rinsing 3 times with 1xPBS 
followed by boiling in distilled water for 3 min, and rinsing 3 times with 1xPBS 
(designated as Riboclear and short boiling) 
5. Treatment with Riboclear for 10 min at 37 C, and rinsing 3 times with 1xPBS, 
followed by treatment with 3% H2O2  for 30 min at room temperature, and rinsing 
3 times with 1xPBS (designated as Riboclear and H2O2) 
6. Treatment with Riboclear for 10 min at 37 C, and rinsing 3 times with 1xPBS, 
followed by heating for 10 min in distilled water at 98 C, and cooling down for 
10 min at room temperature (designated as Riboclear and heating 98 C) 
7. Treatment with 2-ME/SDS solution (0.8%/20%, v/v) for 30 min at 56 C, and 
rinsing 3 times with 1x PBS (designated as 2-ME/SDS) 
8. Treatment with 2-ME/SDS solution (0.8%/20%, v/v) for 30 min at 56 C, and 
washing five times with 1xPBS for 5 min each (extensive washing included in 
order to avoid strong fluorescence from SDS) (designated as 2-ME/SDS 56 C 
and PBS washing) 
Detection of the second target: primary antibody labeling, 
secondary antibody labeling, and Alexa Fluor tyramide labeling 




9. Treatment with 2-ME/SDS solution (0.8%/20%, v/v) for 30 min at 56 C, rinsing 
three times with 1xPBS, and incubation in 2,5% (v/v) Triton X-100 for 10 min 
(designated as 2-ME/SDS 56 C and Triton X-100 washing) 
10. Treatment with 1x citrate buffer pH 6.1 (Dako, cat. S169984-2) in a house hold 
microwave oven (power setting 850W for 2.5 min, then 450W for 5 min) and 
cooling down for 30 min at room temperature), followed by rinsing 3 times with 
1x PBS (designated as microwave treatment). 
4. RESULTS 
 
4.1 Optimization of IF staining for FFPE tissue 
 
Tables 7 and 8 summarize all experiments accomplished for the optimization of IHC 
and single IF protocols for the studied 11 biomarkers. All optimized protocols for single-
IF are presented in Table 10. The main idea of the optimization process of IF was, first, 
to develop basic protocol for single IF which could then be applied for different 
biomarkers, and secondly, optimize pretreatment procedures of tissue and dilutions of 
primary antibodies for individual biomarkers using the optimized basic IF protocol. The 
staining pattern seen in IF was considered reliable when it resembled that obtained 
from IHC. 
 
4.1.1 Optimization of single IF 
 
In order to optimize basic protocol for single IF, two different dilutions of secondary 
antibody and tyramide conjugate were tested (1:50 and 1:100). In these tests, p-mTOR 
primary antibody was used as an example. For further experiments, dilution 1:100 was 
chosen as optimal for both parameters. Figure 6 shows equal staining of epithelial cells 








Figure 6. Equal staining in two protocols for p-mTOR. Different dilutions of secondary antibody 
and tyramide were tested: 1:50/1:50 (A) and 1:100/1:100 (B). Scale bar - 100 µm. 
 
To validate the specificity of the signal obtained from single-IF several controls were 
used: 1) without primary antibody, 2) without primary and secondary antibodies, and 3) 
without primary and secondary antibodies as well as fluorescent tyramide conjugate. In 
each control experiment, omitted reagent was substituted with corresponding diluent 
used in that step of detection. With these tests one can evaluate source of unspecific 
signal possibly detected – cross reactions of detection reagents, insufficient blocking of 
endogenous peroxidase activity in tissue and/or autofluorescence. In this study, most 
of the tested options showed absence of signal indicating that the protocol resulted in 
specific labeling. However, autofluorescence of connective tissue was often observed. 
In epithelial cells – the primary interest in this thesis – autofluorescence was never 









Figure 7. Control stainings with omitted primary antibody (A), primary and secondary antibodies 
(B), and primary and secondary antibodies as well as fluorescent tyramide (C).  Single IF 
including p-mTOR primary antibody and all the detection reagents is shown for comparison (D). 
No signal from cross reactions, endogenous peroxidase activity or autofluorescence is seen. 





Figure 8. Autofluorescence of connective tissue was seen in both green and yellow channels. 
CRC sample was used as an example and protocol was performed omitting primary antibody, 
secondary antibody and tyramide. Scale bar - 100 µm. 
 
In addition, two different Alexa labels were tested for immunofluorescent detection in 
order to compare the signal intensity obtained. p-mTOR primary antibody was used as 
an example (Figure 9). The applicability of the protocol was further tested using 
different type of tissue sample and another primary antibody. Figure 10 shows 






Figure 9. Comparison of staining intensities obtained by using Alexa488, green (A) and 
Alexa555, yellow (B) shows comparative signal in CRC tumor epithelial cells in single IF using 





Figure 10. Single IF using ki67 primary antibody shows proliferating cells in yellow in lymph 




TSA is considered as highly sensitive method. To compare sensitivities between 
detection methods used in IHC and IF, differencies in the dilutions of primary 
antibodies needed to obtain clear signal were contrasted. As expected, higher dilutions 
could be used when applying TSA. For example, 1:200 dilution was required for rabbit 
securin and PTTG1IP primary antibodies and 1:1000 for Ezrin when detected by IHC 
while considerably higher dilutions 1:1000, 1:1500 and 1:20000 could be used in IF for 
the same antibodies, respectively (not shown). 
Some of the fluorescently labelled slides sealed with nail polish were stored in dark at 
+4 C and the signal intensity of the stainings was re-evaluated after one year storage. 
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Figure 11. Signal intensity of different fluorescent labels before (1) and after 1 year of storage 
(2). Alexa555 (yellow) and Alexa488 (green) still showed high signal intensity. DAPI, however, 
was fainted over time. Scale bar - 100 µm. 
 
4.1.2 Optimization of double IF using primary antibodies raised in different host 
species 
 
Double IF can be performed sequentially, meaning that after the detection of the first 
antigen residual peroxidase activity from the first secondary antibody is destroyed, and 
then the second antigen is detected. When the applied primary antibodies are raised in 
different host species cross reaction between the first primary antibody and the second 
secondary antibody is not an issue. However, the complete inactivation of peroxidase 




different treatments were tested in order to test the completeness of the inactivation of 
HRP. Of the tested treatments, 0.3% H2O2, 2% H2O2 and HCl were not sufficient to 
inactivate HRP activity completely. However, 1 min boiling in distilled water was 
enough to inactivate HRP activity and was, therefore, applied in all double IF stainings 
when primary antibodies were raised in different host species. Figure 12 represents 
results of the tests using p-mTOR as an example. In these tests, p-mTOR primary 
antibody was first detected with Alexa555 (yellow), and then HRP was inactivated. 
After this, second primary antibody was substituted with antibody diluent and detected 
with Alexa488 (green). Thus, green signal seen in epithelial cells stems from the 






























Figure 12. Different methods of inactivation of horseradish peroxidase in sequential double 
immunofluorescence using staining of p-mTOR in CRC sample as an example. p-mTOR was 
detected first (Alexa555, yellow) and second primary antibody was substituted with antibody 
diluent (Alexa488, green). 
1, 2 and 3. Insufficient inactivation of HRP activity (0.3% H2O2, 2% H2O2 and HCl, 
respectively) shown with arrows. 
4. One minute boiling inactivated HRP totally, no signal is observed.  





The one minute boiling protocol was chosen for further use and some controls were 
applied to check performance of the developed protocol: 1) omitting primary antibody in 
the second round of detection, 2) omitting all primary and secondary antibodies as well 
as tyramide conjugate in the first round of detection but including tyramide Alexa555 in 
the second round and 3) omitting both primary and secondary antibodies as well as 
tyramide conjugates both in the first and the second rounds of detection. Using these 
controls possible residual HRP activity, cross reactions of antibodies, incomplete 
quenching of endogenous peroxidase activity and autofluorescence can be evaluated. 
All controls demonstrated efficacy of the method since inappropriate signal was not 
detected, except for autofluorescence of connective tissue. Figure 13 shows an 
example of control staining performed omitting primary and secondary antibodies as 
well as tyramide conjugates. 
 
Figure 13. Control for double IF using one minute boiling between the rounds of detection. No 
signal was detected when primary and secondary antibodies and tyramide conjugates were 
omitted, except for autofluorescence of connective tissue in CRC sample. Scale bar - 100 µm.  
In order to test if the signal is affected by boiling, intensity obtained by single IF was 
compared to that remaining after boiling. The signal intensities were comparable as 





Figure 14. Signal intensity obtained from p-mTOR single IF (A) was comparable to that seen 





4.1.3 Optimization of double IF using primary antibodies raised in same host 
species 
To study the possibility to use a pair of antibodies raised in same host species several 
sequential stainings using ki67 and Cleaved caspase 3 primary antibodies were 
performed. Ki67 is a proliferation marker and Cleaved caspase 3 is a marker of 
apoptosis, and therefore, they should not show same expression pattern – unless 
reaction occurs between the primary antibody applied in the first and the secondary 
antibody applied in the second round of detection. For some experiments, Cleaved 
caspase 3 primary antibody was substituted with antibody diluent. In this case, no 
signal from tyramide conjugate applied in the end of sequential double IF should be 
seen. Intermediate steps executed in order to elute / denaturate antibodies used in the 
detection of the first antigen, and thus applied between the sequential detections of 
antigens are shown in Table 2. This table includes also an evaluation of efficiency of 
these treatments. Results are presented in figure 15. 
Table 2. Intermediate steps tested in double IF applying primary antibodies raised in same host 
species and their efficiency. 
Treatment Efficiency 
1 min boiling low 
3 min boiling low 
Riboclear low 
Riboclear and short boiling low 
Riboclear and H2O2   low 
Riboclear and heating 98 C promising 
2-ME/SDS background autofluorescence 
2-ME/SDS 56 C and PBS washing background autofluorescence 
2-ME/SDS 56 C and Triton X-100 washing promising 
Microwave treatment low 
 
Because SDS-containing solution caused heavy background fluorescence, two 
methods were tested in order to remove this fluorescence from specimen – treatment 
with Triton X-100 for 10 min and washing five times with PBS (5 min for each). Of the 
tested methods, Triton X-100 removed background fluorescence better than extensive 


































































Cleaved caspase 3 
 
Figure 15. Staining patterns obtained from sequential double IF applying different methods for 
the inactivation of HRP and denaturation / elution of the primary antibody used in the detection 
of the first antigen. Identically stained areas shown with arrows reveal an undesirable reaction 
between the primary antibody applied in the first and secondary antibody applied in the second 
round of detection. In each experiment, ki67 was applied in the first round of detection and 
labelled with Alexa555 (yellow). Scale bar - 100 µm.  
1. Staining patterns for ki67 and Cleaved caspase 3 demonstrated by single IF 
2. 1 min boiling 
3. 3 min boiling 
4. Riboclear  
5. Riboclear and short boiling  
6. Riboclear and H2O2   
7. Riboclear and heating 98 C 




9. 2-ME/SDS 56 C and PBS washing 
10. 2-ME/SDS 56 C and Triton X-100 washing 
11. Microwave treatment 
 
Because treatment with Riboclear following by heating at 98 C showed promising 
results, it was studied further using another pair of primary antibodies raised in same 
host species. Cytokeratin Pan and Vimentin were chosen for testing. Cytokeratin Pan 
labels epithelial cells while Vimentin labels mesenchymal cells. Double IF using 
Riboclear and heating 98 C, and applying Cytokeratin Pan and Vimentin showed 
promising results when Vimentin was applied in the first round of double IF. Table 3 
describes the tested options and the results obtained.  
 
Table 3. Double IF applying Cytokeratin Pan and Vimentin primary antibodies and treatment with 
Riboclear and heating 98 C to denaturate / elute the first primary antibody.  
 1 2 3 
1st primary antibody Cytokeratin Pan  Vimentin  Vimentin  
1st fluorescent label Alexa488  Alexa488 Alexa555  
2nd primary antibody Vimentin  Cytokeratin Pan  Cytokeratin Pan  
2nd fluorescent label Alexa555  Alexa555  Alexa488  
Result Staining from 
Cytokeratin Pan 
and Alexa555 
No staining from 
Vimentin and 
Alexa555 




Next, double IF including the treatment with Riboclear and heating at 98 C was 
performed substituting the second primary antibody with antibody diluent, and thus 
staining with the second tyramide conjugate should not show any labelling. Different 
pairs of primary antibodies were applied in these tests. Each pair of tested antibodies 
was raised in same host species. These tests included mouse monoclonal (Cytokeratin 
Pan, Vimentin, E-cadherin) and rabbit monoclonal (Cleaved caspase 3) antibodies. Of 
the tested antibodies, Cytokeratin Pan and Cleaved caspase 3 could not be removed 
with the applied treatment. However, Vimentin and E-cadherin were removed totally. 





























Figure 16. Double IF applying different types of primary antibodies and treatment with Riboclear 
and heating at 98 C to denaturate / elute the first primary antibody. The second primary 
antibody applied was substituted with antibody diluent. 
1. Cytokeratin Pan: epithelial cells should be seen only in Alexa488 (green), however reaction is 






2. Cleaved caspase 3: lymphocytes undergoing apoptosis should be seen only in Alexa555 
(yellow), however reaction is observed also in Alexa488 (green) demonstrating incomplete 
removal of the first applied primary antibody. 
3. E-cadherin: epithelial cells are seen only in Alexa488 (green) demonstrating total removal of 
the first applied primary antibody. 
4. Vimentin: connective tissue is seen only in Alexa488 (green) demonstrating total removal of 
the first applied primary antibody. 
Scale bar - 100 µm. 
 
 
Table 4.  Success of the removal of the different types of primary antibodies using Riboclear 
and heating at 98 C.  
Primary antibody Type of the primary antibody Success of the removal  
Cytokeratin Pan mouse monoclonal primary antibody not 
removed 
Cleaved caspase 3 rabbit monoclonal primary antibody not 
removed 
Vimentin mouse monoclonal good, primary antibody 
removed totally 
E-cadherin mouse monoclonal good, primary antibody 
removed totally 
 
4.2 Application of IF for the detection of selected biomarkers in CRC 
All tested conditions to optimize single IF for selected biomarkers in CRC are 
presented in table 9 and the best ones in table 10 in the appendices. For each primary 
antibody, the antigen retrieval procedure and the dilution was optimized separately. 
However, for some antibodies other variables needed additional testing.  
 
4.2.1 EGFR IHC and single IF 
EGFR signaling is considered to play an important role in CRC and it was chosen as 
the main target in this thesis. Two different EGFR antibodies – one raised in mouse 
and the other in rabbit – were used enabling combinations with both rabbit and mouse 
primary antibodies in double IF. Examples of expression patterns from different 
labellings using different EGFR primary antibodies demonstrate corresponding staining 










Figure 17. Different methods of detection and different EGFR primary antibodies in CRC 
samples. 
A. IHC applying EGFR (mouse monoclonal, clone 25) primary antibody 
B. single IF applying EGFR (mouse monoclonal, clone 25) and overnight incubation of 
primary antibody 
C. single IF applying EGFR (rabbit monoclonal, clone 5B7)  
Scale bar - 100 µm. 
 
Special optimization process was required for EGFR (clone 25) primary antibody to 
obtain sufficiently bright signal in single IF. Different combinations of dilutions for 
primary antibody, secondary antibody and fluorescent tyramide conjugate were tested 
in the optimization process (Table 5). 
Table 5. Optimization of EGFR (clone 25) single IF protocol. 
EGFR (clone 25) 1:50 1:25 1:25 
Secondary antibody 1:50 1:100 1:50 
Alexa488 1:50 1:100 1:50 
 
Of the tested combinations, 1:25 (primary antibody) / 1:50 (secondary antibody) / 1:50 
(Alexa488) gave the best signal intensity, and thus, was chosen for further 
immunofluorescence experiments. To further intensify the signal, incubation time of the 
primary antibody was increased from one hour incubation at RT to overnight incubation 
in the fridge at 4 °C. 
Double IF was used to check the similar expression patterns obtained by mouse and 
rabbit EGFR primary antibodies. Different order of primary antibodies and different 
fluorescent dyes were tested. For mouse EGFR (clone 25) primary antibody overnight 
incubation in the fridge was used. (Table 6 and figure 18). Staining patterns were 
similar. 




Experiment 1 2 
First primary antibody EGFR (clone 5B7) EGFR (clone 25) 
First secondary antibody 1:100 1:50 
First tyramide Alexa555,1:100 Alexa488, 1:50 
Second primary antibody EGFR (clone 25) EGFR (clone 5B7) 
Second secondary antibody 1:50 1:100 
Second tyramide Alexa488, 1:50 Alexa555, 1:100 
 
1st applied primary antibody 2nd applied primary antibody 
 
EGFR (clone 25)  
 
EGFR (clone 5B7) 
 
EGFR (clone 5B7) 
 
EGFR (clone 25) 
Figure 18. Double IF using EGFR (clone 5B7, rabbit) and EGFR (clone 25, mouse) primary 
antibodies. Application of EGFR (clone 25) in the second round of detection with Alexa488 and 
overnight incubation at 4 °C showed the brightest signal. Scale bar - 100 µm. 
 
4.2.2 p-mTOR IHC and single IF 
Special antibody diluents are recommended for the detection of phosphorylated 
proteins. Thus, labelling with p-mTOR primary antibody was tested using four different 
antibody diluents: Discovery PSS Diluent, 1% BSA in Discovery PSS Diluent, Antibody 
Diluent by Ventana and DAKO REAL Antibody Diluent. From these, 1% BSA in 
Discovery PSS Diluent showed the highest signal intensity in IHC and was chosen for 




demonstrated in CRC tissue both by IHC and single IF (Figure 19). Staining patterns 
are similar. 
  
Figure 19. p-mTOR is expressed in colorectal cancer cells. Scale bar - 100 µm. 
 
An example of drastic difference in signal intensity in p-mTOR staining after the 





Figure 20. Pretreatment using antigen retrieval buffer pH 6.0 (A) showed weak signal intensity 
in comparison with pH 9.0 (B) in CRC sample using p-mTOR primary antibody. Scale bar - 100 
µm. 
4.2.3 pAKT IHC and single IF 
Two different primary antibodies were tested in the detection of pAKT, since the weak 
signal intensity obtained in IHC. Multiple attempts were performed to optimize 
chromogenic staining using pAKT (phospho S473, clone EP209Y) primary antibody in 
CRC and BC tissue (Table 7 in appendices), but they all were characterized by strong 
background staining or weak target signal intensity. Another antibody – pAKT (473, 
clone D9E) – was applied in single IF according to the recommendation. Different 
incubation times and temperatures needed to be tested for IHC and single IF using this 
antibody in order to intensify the signal obtained. Breast cancer tissue biopsy was used 
in these tests in order to avoid problems related to the detection of phosphoprotein in 
larger tissue samples. Figure 21 demonstrates an example of pAKT staining in BC 












Figure 21. pAKT expression in BC tissue labelled by clone D9E in IHC (A) and  single IF (B). 
Scale bar - 100 µm. 
 
4.2.4 Ezrin IHC and single IF 
The expression pattern obtained by Ezrin primary antibody is demonstrated in figure 
22. IHC and IF provided identical staining pattern. 
  
Figure 22. Ezrin is shown to be expressed in tumor epithelial cells in CRC. Scale bar - 100 
µm. 
 
4.2.5 Double IF of selected biomarkes in CRC 
Expression patterns of selected biomarkers obtained by applying double IF and 
different combinations of primary antibodies in CRC tissue are shown in figure 23.  
Strong Ezrin and strong EGFR cells show stronger p-mTOR staining. EGFR 



















































4.3 Application of IF for the detection of selected biomarkers in BC  
 
All tested conditions to optimize single IF for selected biomarkers in BC are presented 
in table 8 and the best ones in table 9 in the appendices. For each primary antibody, 
the antigen retrieval procedure and the dilution was optimized separately. 
4.3.1 Securin IHC and single IF 
Proliferation is a corner stone in breast cancer pathology. In this study, proliferation 
related protein securin was studied. Two different securin antibodies were tested in 





Figure 24. Comparison of expression patterns of securin in BC tissue shown by IHC and IF 
applying primary antibody clones DSC-280 and EPR 3240. Securin EPR 3240 demonstrated 
additional staining of collagen in basement membrane. Scale bar - 100 µm. A = DSC-280 and B 
= EPR 3240. 
  
Figure 25. Double IF of Securin EPR 3240 (Alexa488, green) and Securin DSC-280 (Alexa555, 




4.3.2 PTTG1IP IHC and single IF 
The expression pattern obtained by PTTG1IP primary antibody is demonstrated in 
figure 26. PTTG1IP showed different expression patterns in different types of breast 
cancer: in low grade carcinomas it was expressed abundantly, whereas in high grade 
carcinomas it was absent. IHC and IF provided identical staining pattern. 
  
Figure 26. PTTG1IP is shown to be expressed in tumor epithelial cells in BC. Scale bar - 100 
µm. 
4.3.3 ki67 IHC and single IF 
The expression pattern obtained by ki67 primary antibody is demonstrated in figure 27. 
IHC and IF provided identical staining pattern. 
  
Figure 27. ki67 is shown to be highly expressed in breast cancer cells. Scale bar - 100 µm.  
4.3.4 Double IF of selected biomarkers in BC 
 
Expression patterns obtained by double IF for securin and PTTG1IP, as well as for 
securin and ki67 are shown in figures 28 and 29. In low grade breast carcinomas, 
securin-expression was seen in single cancer cells whereas Pttg1IP was observed 
diffusely in the majority of cancer cells. In triple-negative subtype of high grade breast 



















Figure 28. Double IF of selected biomarkers in low grade BC samples. 1. Securin DSC-280 and 
ki67. 2. Securin DSC-280 and PTTG1IP. In low grade breast carcinomas, securin-expression 
was seen in single cancer cells whereas Pttg1IP was observed diffusely in the majority of 















Figure 29. Double IF of selected biomarkers in triple-negative (high grade) BC samples. 1. 
Securin DSC-280 and ki67. 2. Securin DSC-280 and PTTG1IP. In triple-negative subtype of 
high grade breast carcinomas securin was highly expressed in the malignant cells but Pttg1IP 






5. DISCUSSION  
 
In this thesis, the main aim was to establish a technique for the visualization of multiple 
antigens in human formalin-fixed paraffin embedded tissue by immunofluorescence. It 
was shown that tyramide signal amplification system can be used to overcome the 
problem of autofluorescence seen in FFPE samples - intense signal from TSA 
exceeded that of biological structures. (Casella et al., 2004.) Notable exception was the 
autofluorescence from the connective tissue. This has been reported also previously 
(Abuduwali et al., 2013). Thus, care must be taken and appropriate control stainings 
must be included when using the developed protocol for the study of connective tissue. 
The experiments done in this study, however, focused mainly in the evaluation of 
biomarkers expressed in epithelial derived of tumor cells. 
One problem of immunofluorescence technique is signal fading during storage (Mackie 
et al., 1980). Here we noticed, however, that signal intensity remains evaluable even 
after 1 year storage. This can be explained by storage in dark, stability and brightness 
of the utilized Alexa dyes, and also by sealing the edges of the coverslip with nail 
polish. Additionally, the applied mounting medium helps to secure the signal. 
In this study, protocols were obtained for single fluorescent detection of ten biomarkers, 
including EGFR, p-mTOR, Ezrin, E-cadherin, Vimentin, Cytokeratin Pan, ki67, Cleaved 
caspase 3, securin and PTTG1IP. However, there were problems in the detection of 
pAkt, most probably, due to the delayed fixation of tissue. Two primary antibodies were 
tested for the detection of pAkt expression, but neither of them was able to show 
intense staining. In addition, small tissue biopsy gave better results compared to larger 
tissue. It is probable that small specimen has been fixed faster. Thus, it is more likely 
that problem is in tissue specimen, not in primary antibody. According to literature, 
phosphoproteins are especially prone to show alterations if fixation is delayed. 
Furthermore, stability of different phosphor-epitopes varies (Baker et al., 2005; 
Gündisch et al., 2011; Holzer et al., 2011).  
In this thesis, sequential detection of two antigens was performed in double IF. In case 
of applying a pair of primary antibodies raised in different host species, there isn’t 
problem of reaction between the first primary antibody and the second secondary 
antibody. However, it must be assured that the activity of the reporter enzyme used in 
the first detection is totally silenced before applying the second substrate on the slide. 
In the present study HRP was used as an reporter enzyme. Recently reported methods 




treatments using H2O2 (Roth K, 2008) and HCl (www.perkinelmer.com, 2015). In my 
experiments, these methods were not efficient enough. However, brief boiling in 
distilled water (Roth K, 2008), in this case 1 min, resulted in sufficient inactivation and 
was then successfully applied for further studies using both for colorectal and breast 
cancer tissues. 
Double IF detection using primary antibodies raised in same host species can be more 
complicated. In addition to the enzyme inactivation process, also the antibodies already 
detected in the first sequence of the detection need to be removed, or their at least 
denatured. Universal commonly applicable method for the elution/denaturation is still 
not found, although numerous approaches have been introduced and their limitations 
studied in literature during the years. According to the data presented in this thesis, 
boiling in distilled water for 1 min was sufficient for the elimination of HRP activity, but 
even 3 min boiling was insufficient for the destruction of antibody itself. However, 
generalization of this result is limited by the number of tested antibodies. Nevertheless, 
ki67 – antibody which couldn’t be removed by boiling – still showed promising results 
when harsher treatment including commercial acidic Riboclear-solution (ventana.com, 
2014) combined with heat treatment was used. Utilization of microwave oven for the 
elimination of antibodies is known for decades (Lan et al., 1995), but the efficiency of 
this treatment remains still controversial (Bauer et al., 2001; Ikeda et al., 2011). In the 
experiments performed in this thesis, the method was not found efficient. But as with 
boiling, the result is limited by the number of tested antibodies. Elution using 2-ME/SDS 
is considered as a highly effective method for many antibodies, however, conditions 
required for successful elution have been shown to depend on the antibody affinity 
(Gendusa et al., 2014). In the current study, this method was considered rather 
efficient. The background fluorescence caused by SDS, however, disturbed the 
evaluation of the results. The idea to diminish fluorescence caused by SDS using 
Triton-X 100 was proposed by Lee et al. in  (1978) for immunoelectroforetic analysis 
and was applied in this study for IF. The usage of Triton helped to decrease the 
background fluorescence, but it was not totally removed. Further experiments on this 
area could be beneficial since the results using the method were promising. According 
to Van der Loos (2008) heating at 98 C for 10 min followed by cooling down to 75 C 
is sufficient to remove some antibodies. In this study, this treatment was used in 
combination with acidic Riboclear-solution, and it proved to be efficient for several, but 
not for all, tested antibodies. The observed differences in the efficiency of 
elution/denaturation depend most likely on the individual characteristics, such as 
affinity (Gendusa et al., 2014), of the primary antibodies. Sometimes, the problem of 




order. For example, it was shown in this study that Cytokeratin Pan or Cleaved 
caspase 3 are recommended to be applied as late as in the second round of sequential 
double IF, whereas Vimentin, E-cadherin and ki67 can be applied in the first round 
since the treatment using Riboclear and heat was able to remove these antibodies. 
As a summary, double IF was shown to be readily conducted when a pair of primary 
antibodies raised in different host species was applied. However, a universal procedure 
for a pair of primary antibodies raised in same host species was not found, although 
the combination of acidic solution Riboclear produced by Ventana and heating at 98 C 
was shown to be suitable for some antibodies. In this thesis, only manual setting of 
fluorescent labelling was used but the gathered experiences can be readily adapted in 
future when transferring the stainings into the automated Discovery XT platform 
(Ventana). The tested combination of commercially available reagent Riboclear 
followed by heating can be easily performed on this platform. Automation of whole 
procedure from deparaffinization to fluorescent labelling of two antigens will help to 
resolve the problem of time-consuming and labor intensive optimization of double IF.  
Multicolor immunofluorescence could be a beneficial tool for pathological diagnostics. 
However, the method is complicated. Present data indicated the possibility of 
simultaneous detection of two biomarkers in FFPE colorectal and breast cancer tissues 
shown by successful stainings applying many different primary antibody pairs raised in 
different host species (EGFR (clone 25)/p-mTOR, Ezrin/EGFR (clone 5B7), p-
mTOR/Ezrin, Cytokeratin Pan/EGFR (clone 5B7), p-mTOR/Vimentin, p-mTOR/E-
cadherin, Securin DSC-280/ki67 and Securin DSC280/PTTG1IP). Furthermore, double 
IF detection was also achieved in one pair of primary antibodies raised in same host 
species (Vimentin/Cytokeratin Pan). In this thesis, it has been shown that p-mTOR and 
EGFR were expressed in same tumor epithelial cells in CRC. Additionally, p-mTOR 
and Ezrin, p-mTOR and E-cadherin were co-expressed in cancer cells. However, p-
mTOR was found in different tumor epithelial cells, and Vimentin was observed in 
mesenchymal cells. Same was true for EGFR and Cytokeratin Pan, as well as, for 
EGFR and Ezrin. In breast cancer, high proliferation shown by ki67 was associated 
with more numerous securin positive cells in tumor, although ki67 positivity was always 
found to exceed that of securin. In addition, low grade carcinomas were shown to 
express less securin compared to high grade cases. This was known already from 
literature (Talvinen et al., 2008). On the contrary, high expression of PTTG1IP was 
associated with low grade cancer, while high grade triple-negative subgroup showed 






Protocols for the visualization of many biomarkers in formalin-fixed paraffin embedded 
colorectal cancer and breast cancer samples using multicolor immunofluorescence 
method were developed and optimized. Detection of multiple markers in cancer tissues 
using these protocols could have an important role in translation to medical 
diagnostics. In this study, however, a limited number of antibodies, and especially a 
limited number of patient cases, were tested. To summarize the achieved results: 
1. Single IF was successful, autofluorescence from connective tissue, however, 
must be controlled. 
2. Double IF using a pair of primary antibodies raised in different host species was 
successful. 
3. Double IF using a pair of primary antibodies raised in same host species was 
occasionally successful depending on the characteristics of the individual 
primary antibodies.  
4. Application of multiple markers in the CRC cases was meaningful and provided 
information of the activation of signaling cascades in EGFR expressing cancer 
cells. In breast cancer, especially expression pattern of PTTG1IP was 
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Table 7. Different combinations of conditions tested in the optimization of immunohistochemistry protocols 














EGFR.25  CRC sCC1 1:100 Ventana 36 20 
mCC2 1:100 Ventana 36 20 
mCC2 1:50 Ventana 36 20 
mCC2 1:50 Ventana 44 24 
mCC2 1:50 Ventana 52 24 
mCC2 1:50 Ventana 120 24 
mCC2 1:30 Ventana 52 24 
Manual 1:50 Ventana 52 24 
pAKT 
EP209Y 
CRC mCC1 1:100 PSS 36 20 
mCC2 1:100 PSS 36 20 
sCC1 1:100 PSS 36 20 
mCC2 1:50 Ventana 32 12 
DAKO diluent 12 min, mCC2 1:50 Ventana 48 24 
pAKT 
EP209Y 
BC mCC1 1:50 PSS 48 24 
mCC2 1:50 PSS 48 24 
sCC1 1:50 PSS 48 24 
Protease 3, 16 min 1:50 PSS 48 24 
Citrate buffer (pH 6.0) 32 min,sCC1 1:50 PSS 48 24 
DAKO diluent 12 min, mCC2 1:50 Ventana 48 24 
DAKO diluent 12 min, mCC2 1:50 DAKO 48 24 
DAKO diluent 12 min, mCC2 1:50 DAKO 60 RT 24 
pAKT  
D9E  
BC mCC1 1:100 Ventana 36 20 
mCC2 1:100 Ventana 36 20 




sCC1 1:200 PSS 36 20 
sCC1 1:50 DAKO 36 20 
sCC1 1:100 DAKO 36 20 
sCC1 1:200 DAKO 36 20 
sCC1 1:50 Ventana 36 20 
sCC1 1:100 Ventana 36 20 
sCC1 1:200 Ventana 36 20 
sCC1 1:50 














mCC1 1:1000 Ventana 36 20 
Securin rb BC  mCC1 1:100 Ventana 36 20 
mCC1 1:200 Ventana 36 20 
mCC2 1:100 Ventana 36 20 
mCC2 1:200 Ventana 36 20 
PTTG1IP 
 
BC  mCC1 1:100 Ventana 36 20 
mCC1 1:200 Ventana 36 20 
mCC2 1:100 Ventana 36 20 
mCC2 1:200 Ventana 36 20 
mCC1 - mild cell conditioning 1, mCC2 - mild cell conditioning 2, sCC1 - standard cell conditioning 1, sCC2 - standard cell conditioning 2. 






Table 8. Different combinations of conditions tested in single immunofluorescence protocols 















EGFR.25  CRC 6.0 
1:25, 4 C 
overnight 
Ventana 1:50 Alexa488 1:50 Positive 
 
CRC 6.0 
1:200, 4 C 
overnight 
Ventana 1:50 Alexa488 1:50 Negative 
 
CRC 6.0 1:50 Ventana 1:50 Alexa488 1:50 Negative 
 
CRC 6.0 1:50 Ventana 1:50 Alexa555 1:50 Negative 
 
CRC 6.0 1:50 Ventana 1:50 Alexa488 1:50 Negative 
 
CRC 6.0 1:25 Ventana 1:100 Alexa488 1:100 Negative 
 
CRC 6.0 1:25 Ventana 1:50 Alexa488 1:50 Negative 
















Ventana 1:100 Alexa488 1:100 Positive 
p-mTOR  2448 (49F9) CRC 9.0 1:100 
1% 
BSA/PSS 





CRC 6.0 1:100 
1% 
BSA/PSS 
1:100 Alexa488 1:100 Positive 




Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:5 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:10 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:50 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:100 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:500 Ventana 1:100 Alexa488 1:100 Negative 
E-cadherin NCH-38  CRC 9.0 1:100 Ventana 1:100 Alexa488 1:100 Positive 
Cytokeratin Pan AE1/AE3 CRC 9.0 1:200 Ventana 1:100 Alexa555 1:100 Positive 
 
CRC 9.0 1:200 Ventana 1:100 Alexa488 1:100 Positive 
pAKT 473 D9E BC 9.0 




1:100 Alexa555 1:100 Low 
Ezrin 3C12 CRC 9.0 1:1000 Ventana 1:100 Alexa555 1:100 Positive 
 
CRC 9.0 1:1500 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:3000 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:10000 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:20000 Ventana 1:100 Alexa488 1:100 Positive 
 
CRC 9.0 1:50000 Ventana 1:100 Alexa488 1:100 Negative 
Securin DSC-280 BC 6.0 1:150 Ventana 1:100 Alexa555 1:100 Positive 
 





BC 9.0 1:150 Ventana 1:100 Alexa488 1:100 Positive 
Securin EPR 3240 BC 6.0 1:1000 Ventana 1:100 Alexa555 1:100 Positive 
 
BC 6.0 1:1000 Ventana 1:100 Alexa488 1:100 Positive 
 
BC 9.0 1:100 Ventana 1:100 Alexa555 1:100 Positive 
PTTG1IP  BC 6.0 1:1500 Ventana 1:100 Alexa555 1:100 Positive 
Cleaved caspase 3 D3E9 LN 9.0 1:100 Ventana 1:100 Alexa488 1:100 Positive 
ki67  LN 9.0 1:1000 Ventana 1:100 Alexa555 1:100 Positive 
 
LN 9.0 1:2000 Ventana 1:100 Alexa488 1:100 Positive 
Primary antibody incubation is done at RT (except for those which are 4 C). 
 
Table 9. Optimized protocols for single immunofluorescence 
Primary antibody Tissue 
Antigen 
retrieval 







Alexa Dilution of Alexa 
EGFR.25  CRC 6.0 1:25, 4 C overnight Ventana 1:50 Alexa488 1:50 










Ventana 1:100 Alexa488 1:100 





CRC 6.0 1:100 1% BSA/PSS 1:100 Alexa488 1:100 
Vimentin V9 790-2917  CRC 9.0 1:100 Ventana 1:100 Alexa488 1:100 
E-cadherin NCH-38  CRC 9.0 1:100 Ventana 1:100 Alexa488 1:100 
Cytokeratin Pan AE1/AE3,  CRC 9.0 1:200 Ventana 1:100 Alexa555 1:100 
 
CRC 9.0 1:200 Ventana 1:100 Alexa488 1:100 
Ezrin 3C12 CRC 9.0 1:1000 Ventana 1:100 Alexa555 1:100 
 
CRC 9.0 1:20000 Ventana 1:100 Alexa488 1:100 
Securin DSC-280 BC 6.0 1:150 Ventana 1:100 Alexa555 1:100 
 
BC 6.0 1:150 Ventana 1:100 Alexa488 1:100 
Securin EPR 3240 BC 6.0 1:1000 Ventana 1:100 Alexa555 1:100 
 
BC 6.0 1:1000 Ventana 1:100 Alexa488 1:100 
PTTG1IP BC 6.0 1:1500 Ventana 1:100 Alexa555 1:100 
Cleaved caspase 3 D3E9 LN 9.0 1:100 Ventana 1:100 Alexa488 1:100 
ki67  LN 9.0 1:1000 Ventana 1:100 Alexa555 1:100 
Primary antibody incubation is done at RT (except for those which are 4 C). 
 




First Alexa Second primary antibody Second Alexa 
Efficacy of 
destruction 
1 min boiling ki67 Alexa555 Cleaved caspase 3 Alexa488 low 
1 min boiling ki67 Alexa555 Antibody diluent Alexa488 low 
3 min boiling ki67 Alexa555 Cleaved caspase 3 Alexa488 low 




Microwave treatment ki67 Alexa555 Cleaved caspase 3 Alexa488 low 
Riboclear  ki67 Alexa555 Cleaved caspase 3 Alexa488 low 
Riboclear and short boiling ki67 Alexa555 Cleaved caspase 3 Alexa488 low 
Riboclear and H2O2  ki67 Alexa555 Cleaved caspase 3 Alexa488 low 
Riboclear and heating 98 C ki67 Alexa555 Cleaved caspase 3 Alexa488 promising 
Riboclear and heating 98 C Cytokeratin Alexa555 Vimentin Alexa488 low 
Riboclear and heating 98 C Vimentin Alexa488 Cytokeratin Alexa555 high 
Riboclear and heating 98 C Antibody diluent Alexa555 Vimentin Alexa488 high 
Riboclear and heating 98 C Cytokeratin Alexa555 Antibody diluent Alexa488 low 
Riboclear and heating 98 C Vimentin Alexa555 Cytokeratin Alexa488 high 
Riboclear and heating 98 C Vimentin Alexa488 Antibody diluent Alexa555 high 
Riboclear and heating 98 C Cytokeratin Alexa488 Vimentin Alexa555 low 
Riboclear and heating 98 C Cytokeratin Alexa488 Antibody diluent Alexa555 low 
Riboclear and heating 98 C Cleaved caspase 3 Alexa555 Antibody diluent Alexa488 low 
Riboclear and heating 98 C E-cadherin Alexa488 Antibody diluent Alexa555 high 




ME/SDS 56C and PBS and Triton X-100 
washing 
ki67 Alexa555 Cleaved caspase 3 Alexa488 promising 
ME/SDS 56C and PBS and Triton X-100 
washing 








Table 11. Application of different antibodies in the best denaturation method Riboclear and heating 98 C 
First primary antibody Type of antibody First Alexa 
Second primary 
antibody 
Type of antibody Second Alexa 
Efficacy of 
destruction 
ki67 rabbit polyclonal Alexa555 Cleaved caspase 3 rabbit monoclonal Alexa488 promising 
Cytokeratin Pan mouse monoclonal Alexa555 Vimentin mouse monoclonal Alexa488 low 
Vimentin mouse monoclonal Alexa488 Cytokeratin Pan mouse monoclonal Alexa555 high 
Antibody diluent - Alexa555 Vimentin mouse monoclonal Alexa488 high 
Cytokeratin Pan mouse monoclonal Alexa555 Antibody diluent - Alexa488 low 
Vimentin mouse monoclonal Alexa555 Cytokeratin Pan mouse monoclonal Alexa488 high 
Vimentin mouse monoclonal Alexa488 Antibody diluent mouse monoclonal Alexa555 high 
Cytokeratin Pan mouse monoclonal Alexa488 Vimentin mouse monoclonal Alexa555 low 
Cytokeratin Pan mouse monoclonal Alexa488 Antibody diluent - Alexa555 low 
Cleaved caspase 3 rabbit monoclonal Alexa555 Antibody diluent - Alexa488 low 
E-cadherin mouse monoclonal Alexa488 Antibody diluent - Alexa555 high 
Appendix 1. Calculations for 2% H2O2 











𝑥 =  
75 𝑚𝑙 ×  2%
30 %
 
𝑥 = 5 𝑚𝑙 𝑜𝑓 30%    𝐻2  𝑂2 
Appendix 2. Calculations for 0.01 M HCl 
The volume of HCl was calculated as the following: 
𝑐 = 0.01 𝑀 𝐻𝐶𝑙, ɷ = 37% 𝐻𝐶𝑙, ⍴ = 1,184
𝑔
𝑐𝑚3









𝑚𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑠𝑢𝑠𝑡𝑎𝑛𝑐𝑒 = ɷ × 𝑚𝑠𝑜𝑙𝑢𝑡𝑖𝑜𝑛 
𝑚𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑠𝑢𝑠𝑡𝑎𝑛𝑐𝑒 = 0.37 × 1,184
𝑔
𝑐𝑚3
= 0.44 𝑘𝑔 = 440𝑔 
𝑐 = 𝑚𝑑𝑖𝑠𝑠𝑜𝑙𝑣𝑒𝑑 𝑠𝑢𝑏𝑠𝑡𝑎𝑛𝑐𝑒 ÷ 𝑀𝑊 ÷ 𝑉 
𝑐 = 440𝑔 ÷ 36.59
𝑔
𝑚𝑜𝑙












0.1𝑙 × 0.01 𝑀
12.06 𝑀






Appendix 3. Calculation for 3% H2O2 











𝑥 =  
75 𝑚𝑙 ×  3%
30 %
 
𝑥 = 7,5 𝑚𝑙 𝑜𝑓 30%    𝐻2  𝑂2 
 
Appendix 4. Calculations for Tris-HCl buffer pH 6.8 








 ; 𝑛 = 𝑐 × 𝑉  
Substituting n  from the second formula to the first was calculated the required weight of 
Trisma base: 
𝑚 = 𝑐 × 𝑉 × 𝑀  
𝑚 = 0.5 𝑀 × 0.5𝑙 × 121,14
𝑔
𝑚𝑜𝑙
 ;  𝑚 = 30.1 𝑔 
The buffer was calibrated to pH 6.8 using HCl. 
 
Appendix 5. Prerapation of peroxidase quenching buffer 
10x PBS - 7,5 ml; distilled water - 60 ml; 30% H2O2  - 7,5 ml.  
Appendix 6. Prerapation of BSA. 
1x PBS - 5ml; BSA - 0,05 g. 




80g NaCl , 2g KCl 144g,  Na2HPO4 and 2,4g KH2PO4). pH was adjusted to 7.4 using 5M 
sodium hydroxide. 
Appendix 8. Preparation of 2-ME/SDS solution 
20 ml of 10% w/v SDS (10g of SDS in 100ml of distilled water), 12,5ml of 0.5 M Tris-HCl, 
67.5ml of distilled water and 0.8 ml of 2-ME.  
 
 
 
 
